2025 Venture Competitions Are Open Now for Early-Stage Oncology Companies Worldwide!

The 2025 AIM-HI Venture Competitions are open now to receive applications from early-stage oncology companies worldwide seeking pre-seed, seed, and Series A investments.

Benefits of participating in the competition include:

• Interacting with and receiving valuable feedback from the selection and judging committee members, who are key opinion leaders in the oncology field.
• Access to free, virtual workshop series provided by our partner, Cooley, on topics such as Corporate Legal Basics, IP Protection for Start-Ups, Legal Pitfalls for Start-Ups to Avoid, & Life Science University Transactions/ Licensing
• Top winners will be awarded honorariums, recognized with certificates, and considered for further investment, subject to rigorous due diligence conducted by our Investment Committee.
• The winners will gain recognition and presentation opportunities within the oncology research community, facilitating networking and collaboration opportunities with global cancer experts and investors.
• The winners who pass the due diligence process will be eligible to receive investment from AIM-HI and co-investors; the process itself will also help the company assess and refine its IP and strategy, clinical development plan, and position itself well for other investors.

Learn More about the AIM-HI Venture Competitions and APPLY TODAY!